This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
At DrugBank, we’re dedicated to empowering pharmaceutical researchers with data that drives impactful results. Your Need for Accessible, High-Quality Data—Solved Pharmaceutical research and healthcare innovation demand timely access to comprehensive, up-to-date data. In fact, poor data quality is estimated to cost U.S.
Let’s dive into the world of pharmaceutical outsourcing and explore why adaptability is the key to success. The Evolving Role of CDMOs in the Pharmaceutical Industry Gone are the days when CDMOs were mere service providers. Responding to Market Demands The pharmaceutical market is notoriously unpredictable.
This growth has created a competitive landscape where pharmaceutical companies must carefully evaluate and select the right CDMO partner to ensure the success of their projects. Speed and Quality of Development and Production The speed and quality of development and production are critical considerations in selecting a CDMO.
The pharmaceutical industry is known for its complex regulatory environment and lengthy product development processes. These patents can provide opportunities for companies to bring new products to market at a lower cost and with reduced development time.
Inhaled combination products (ICP) have emerged as a significant advancement in the treatment of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and other pulmonary conditions. However, these products present unique challenges from a Chemistry, Manufacturing, and Controls (CMC) standpoint.
India has long been recognized as a significant player in the global pharmaceutical industry, particularly in the production of generic drugs. The country’s pharmaceutical sector has experienced substantial growth over the years, driven by both domestic and international demand for affordable and high-quality medicines.
International License Abstract Development of generic drug product…. The post Development of Generic Drug Products by Pharmaceutical Industries Considering Regulatory Aspects: A Review appeared first on DrugPatentWatch - Make Better Decisions.
In the face of impending patent expirations, pharmaceutical companies can adopt key approaches to preserve meaningful… The post Strategies to Maximize Product Value Amid Loss of Exclusivity in the Pharmaceutical Industry appeared first on DrugPatentWatch - Make Better Decisions.
In the vast realm of pharmaceutical research and development, there’s a fascinating intersection between ancient wisdom and modern science. “Pharmacognosy is the bridge between traditional medicine and modern pharmaceutical science, offering a treasure trove of potential new drugs waiting to be discovered.”
Between 2000 and 2020, approximately 30 percent of the newly introduced small molecule drugs were derived from natural products. In recent decades there has been a decline in interest in natural products for drug discovery, with the industry gravitating towards screening libraries of synthetic molecules with predefined chemistries.
Identifying branded drugs with a low likelihood of generic entry has become a crucial strategy for companies looking to expand their product portfolio through in-licensing. This approach not only helps maintain market exclusivity but also ensures a steady revenue stream for pharmaceutical companies.
Through a series of exclusive interviews and a survey of industry insiders, Connect in Pharma names the top pharmaceutical and manufacturing-related trends of 2023
AI is influencing all industries, but its impact will be especially strong in pharmaceuticals where it is expected to accelerate drug discovery and, in clinical settings, generate patterns and insights from vast quantities of patient data to enable more personalised treatments.As
Investment Trends in Pharmaceutical Research and Development Investing in the pharmaceutical sector presents a unique set of challenges and opportunities; let’s examine them in more detail. Pharmaceutical Market Analysis The global pharmaceutical market revenue in 2024 is projected to be 1.15 billion by 2030.
Deal Structuring Deal structuring in pharmaceutical M&A requires a balance of financial, legal, and strategic considerations. These structures are particularly relevant in dealing with uncertainty about the future commercial potential of the target's products.
The pharmaceutical industry, particularly the generic drug sector, faces significant challenges in adopting sustainable practices. This includes developing higher-value generics, investing in innovation, and creating differentiated products. GREENER Pharmaceuticals for More Sustainable Healthcare. Retrieved from [link] Pfizer.
Your Guide to the Ultimate PharmaceuticalProduct Improvement Tool This white paper will review how automating the annual product quality review (APQR) process can help pharmaceutical companies simplify and optimize their product quality review process, to make informed product quality decisions quicker and on a more routine and proactive basis.
The Dark Side of Innovation: How Companies Use Drug Patents to Block Competitors As we celebrate the breakthroughs in medical research and the development of life-saving treatments, it's essential to acknowledge the complex landscape of pharmaceutical innovation. One of the most effective tools in their arsenal is the use of drug patents.
A review article in the Journal of Pharmaceutical Sciences analyzes the trends in drug repurposing through the 505(b)(2) pathway, as approved by the USFDA from 2010 to 2020.
Enhancing Your Product Portfolio with CDMOs: A Strategic Partnership for Pharmaceutical Success The pharmaceutical industry is constantly evolving, driven by advancements in technology, innovations in product development, and the need for efficient manufacturing processes.
Michael discusses patient support challenges that are unique to specialty-lite pharmaceuticals. Today’s guest post comes from Michael Carr, CoAssist Group Vice President at AssistRx. He goes on to describe four new categories of patient solutions and pharmacy models specific to this growing market segment.
Date: June 12, 2024 Location: San Diego, CA ProductLife Group (PLG), a leading provider of product development and compliance services in the pharmaceutical and biotechnological sectors, is excited to announce a comprehensive solution aimed at transforming the landscape of drug development, underscoring PLG's commitment to advancing healthcare through (..)
Indeed, most Center for Veterinary Medicine (CVM) Warning Letters arise because products advertised are actually new animal drugs. The Warning Letter alleged that the veterinarian product website made claims about a Vaccine Safety Study relied upon for approval that directly conflict with the PI.
This chart shows the companies which have received the most New Product exclusivities in the past five years. New Product Development is one of the categories for which the FDA grants three years of…
This article aims to provide a comprehensive overview of the key aspects of the regulatory framework, highlighting the requirements and challenges faced by pharmaceutical companies seeking to introduce generic drugs into the Japanese market. Retrieved from [link] Japan Pharmaceutical Manufacturers Association. Freyr Solutions.
China has emerged as a significant player in the global generic drug active pharmaceutical ingredient (API) market. The country’s vast production capacity, low costs, and strategic location have made it an attractive destination for pharmaceutical companies seeking to source APIs.
While most biologically active macrocycles are peptides or natural product-derived , ring-closing metathesis (RCM) reactions have contributed to greater accessibility of unnatural macrocycles in medicinal chemistry. RCM is now used in over half of macrocyclic kinase inhibitor syntheses , for example. M) at 40 °C.
This legislation emerged from a pressing need to address “orphan” conditions, i.e., conditions that were abandoned or “orphaned” by the pharmaceutical industry, deemed unprofitable due to the small number of affected patients (fewer than 200,000 Americans).
Maximizing Patent Protection: Strategies for Pharmaceutical Marketers As a pharmaceutical marketer, you know how crucial it is to protect your patented drug's market share. In this post, we'll explore effective strategies for maximizing patent protection and exclusivity, ensuring your product remains a leader in the market.
The study, forthcoming in the Journal of Marketing, is titled “Scientific Evidence Production and Specialty Drug Diffusion” and is authored by Demetrios Vakratsas and Wei-Lin Wang. A notable trend in the pharmaceutical industry is the development of specialty drugs to […]
Unlock the Secrets to a Successful Generic Drug Launch Are you a pharmaceutical executive looking to bring a generic version of a popular medication to market? In today's highly competitive pharmaceutical industry, generic drug launches can be a game-changer for companies looking to increase market share and revenue.
William Studier for development of widely used protein- and RNA-production platform By Corie Lok May 14, 2024 Breadcrumb Home Merkin Prize in Biomedical Technology awarded to F. Merkin Prize in Biomedical Technology awarded to F. and around the world.
Introduction Patent portfolios are critical assets for pharmaceutical companies, providing market exclusivity and protecting revenue streams for drug products. Effective management of drug patent portfolios requires strategic planning, ongoing evaluation, and adaptation to the evolving pharmaceutical landscape.
Today’s guest post comes from Nasir Ali, Chief Product Officer at CareMetx. Nasir discusses how hubs help patients initiate and adhere to drug therapies. Based on CareMetx research, he outlines the key factors that drug manufacturers value in their hub partners.
Roadmap to Product Launch and Commercialization in Europe pesurya Thu, 04/03/2025 - 10:38 Wed, 05/21/2025 - 11:00 Resource Type Webinar Marie-Charlotte von Brevern Eva Keck Chris Englerth Europe presents a dynamic and growing market for U.S. companies seeking to expand their reach and to bring innovative treatments to patients.
Revolutionizing Generic Drug Development: The Power of Digital Transformation As the pharmaceutical industry continues to evolve, one thing is clear: digital transformation is no longer a luxury, but a necessity. For years, generic drug manufacturers have relied on traditional methods to develop and launch new products.
Environmental Impacts of Traditional PharmaceuticalProduction Traditional pharmaceutical manufacturing is complex, with each phase contributing to environmental degradation. The extraction and synthesis of active pharmaceutical ingredients (API) utilize vast amounts of water and energy.
In the complex world of intellectual property and pharmaceutical development, understanding the intricacies of patent term extension (PTE) is crucial for innovators and businesses alike. This comprehensive guide will delve into… Source
The pharmaceutical industry has witnessed significant advancements in recent years, particularly in the realm of advanced manufacturing technologies (AMTs). These innovations aim to enhance drug quality, efficiency, and customization.
Pharmaceutical tariffs of 25% have been forecasted causing many global organizations to investigate the consequences of the tariffs on their overall product portfolio. The US Government recently modified their policy to utilize tariffs to in an effort to support the US economy.
Cost estimation in drug product manufacturing is far from straightforward. Striking the right balance between operational efficiency and budget constraints poses a significant challenge for pharmaceutical companies. Raw materials, labor, equipment, and quality and regulatory compliance all contribute to a complex web of expenses.
These products contain the same active ingredients as their brand-name counterparts but are typically sold at a lower price point. Branded generics can be an attractive option for both consumers and pharmaceutical companies, offering cost savings while leveraging brand recognition. […] Source
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content